Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 15 mg - tablet, uncoated - excipient ingredients: purified water; povidone; potato starch; ethanol; docusate sodium; magnesium stearate; lactose monohydrate; colloidal anhydrous silica - for temporary relief of acute moderate pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - bisoprolol fumarate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; iron oxide red; maize starch; microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - bisoprolol fumarate, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; crospovidone; magnesium stearate; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - potassium clavulanate, quantity: 148.875 mg; amoxicillin trihydrate, quantity: 1006.25 mg - tablet, film coated - excipient ingredients: ethylcellulose; isopropyl alcohol; microcrystalline cellulose; purified talc; dichloromethane; magnesium stearate; propylene glycol; croscarmellose sodium; hypromellose; titanium dioxide; hyprolose; industrial methylated spirit - medreich co-amoxiclav 500/125 and medreich co-amoxiclav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - potassium clavulanate, quantity: 148.875 mg; amoxicillin trihydrate, quantity: 575 mg - tablet, film coated - excipient ingredients: propylene glycol; dichloromethane; hypromellose; magnesium stearate; croscarmellose sodium; ethylcellulose; purified talc; isopropyl alcohol; microcrystalline cellulose; titanium dioxide; hyprolose; industrial methylated spirit - medreich co-amoxiclav 500/125 and medreich co-amoxiclav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - domperidone maleate, quantity: 12.72 mg (equivalent: domperidone, qty 10 mg) - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; sodium lauryl sulfate; maize starch; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate - medreich domperidone is indicated for the short-term treatment in adults of:,? symptoms associated with idiopathic or diabetic gastroparesis (once control of diabetes has been established by diet and/or insulin, an attempt should be made to discontinue medreich domperidone).,? intractable nausea and vomiting from any cause.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; pregelatinised starch; crospovidone; microcrystalline cellulose; meglumine; purified water; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 10.42 mg (equivalent: rosuvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; pregelatinised starch; meglumine; purified water; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; meglumine; pregelatinised starch; microcrystalline cellulose; purified water; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - medreich rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,medreich rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). medreich rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,medreich rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with medreich rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.